PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14686975-3	2003	Orally administered bexarotene, the first synthetic highly selective retinoid-X-receptor retinoid to be approved by the FDA for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL.	Bexarotene	20-30	TSPY like 2	Homo sapiens	128-132	
14686975-3	2003	Orally administered bexarotene, the first synthetic highly selective retinoid-X-receptor retinoid to be approved by the FDA for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL.	Bexarotene	20-30	TSPY like 2	Homo sapiens	211-215	
14686975-5	2003	Bexarotene treatment induces apoptosis of CTCL cells with down-regulation of its receptors and of survivin, an inhibitor of apoptosis.	Bexarotene	0-10	TSPY like 2	Homo sapiens	42-46